Medical News Today: How skin cancer becomes invasive

Medical News Today: How skin cancer becomes invasive

Publication date: Feb 01, 2019

A new study has finally identified a mechanism that allows skin cancer to become aggressive. The discovery also suggests a novel therapeutic approach.

Publication date: April 2019Source: European Polymer Journal, Volume 113Author(s): Dorota Lachowicz, Alicja Karabasz, Monika Bzowska, Michał Szuwarzyński, Anna Karewicz, Maria NowakowskaAbstractThe bioconjugate of alginate and curcumin (AA-CUR) was synthesized in a simple, one-step process and used to prepare the stable calcium cross-linked spherical micelles serving as a delivery vehicle for curcumin. Above its critical micelle concentration (0.6 mg/ml) AA-CUR forms colloidally stable micelles of ca. 200 nm. Prolonged, well controlled release of curcumin was observed from the AA-CUR micelles cross-linked with calciu…

TNFα mediated ceramide generation triggers cisplatin induced apoptosis in B16F10 melanoma in a PKCδ independent manner. Oncotarget. 2018 Dec 28;9(102):37627-37646 Authors: Ghosh S, Jawed JJ, Halder K, Banerjee S, Chowdhury BP, Saha A, Juin SK, Majumdar SB, Bose A, Baral R, Majumdar S Abstract Ceramide is one of the important cellular components involved in cancer regulation and exerts its pleiotropic role in the protective immune response without exhibiting any adverse effects during malignant neoplasm. Although, the PKCδ-ceramide axis in cancer cells has been an effective target in r…

Lopinavir-NO, a nitric oxide-releasing HIV protease inhibitor, suppresses the growth of melanoma cells in vitro and in vivo SummaryWe generated a nitric oxide (NO)-releasing derivative of the anti-HIV protease inhibitor lopinavir by linking the NO moiety to the parental drug. We investigated the effects of lopinavir and its derivative lopinavir-NO on melanoma cell lines in vitro and in vivo. Lopinavir-NO exhibited a twofold stronger anticancer action than lopinavir in vitro. These results were successfully translated into syngeneic models of melanoma in vivo, where a significant reduction in tumour volume was observed only in animals treated with lopinavir-NO. Both lopinavir and lopinavir-NO inhibited cell proliferation and induced the trans-di…

KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development AbstractMetastatic melanoma is a heterogenous disease that has served as a model for the development of both targeted therapy and immunotherapy. KIT-mutated melanoma represents a rare subset, most commonly arising from acral, mucosal, and chronically sun-damaged skin. Additionally, KIT alterations are enriched in the triple wild-type subtype of cutaneous melanoma. Activating alterations of KIT -a transmembrane receptor tyrosine kinase important for cell development, growth, and differentiation-have been shown to be critical to oncogenesis across many tumor subtypes. Following the successes of BRAF-targeted ther…

oth Tibor Krenacs The incidence of malignant melanoma, one of the deadliest cancers, continues to increase. Here we tested connexin (Cx) expression in primary melanocytes, melanoma cell lines and in a common nevus, dysplastic nevus, and thin, thick, and metastatic melanoma tumor progression series involving the tumor microenvironment by utilizing in silico analysis, qRT-PCR, immunocyto-/histochemistry and dye transfer tests. Primary melanocytes expressed GJA1/Cx43, GJA3/Cx46 and low levels of GJB2/Cx26 and GJC3/Cx30.2 transcripts. In silico data revealed downregulation of GJA1/Cx43 and GJB2/Cx26 mRNA, in addition to …

Cannabinoids as a Potential New and Novel Treatment for Melanoma: A Pilot Study in a Murine Model. CONCLUSIONS: We demonstrate a potential beneficial therapeutic effect of cannabinoids, which could influence the course of melanoma in a murine model. Increased survival and less tumorgenicity are novel findings that should guide research to better understand the mechanisms by which cannabinoids could be utilized as adjunctive treatment of cancer, specifically melanoma. Further studies are necessary to evaluate this potentially new and novel treatment of malignant melanoma. PMID: 30691796 [PubMed – in process]

(Boston University School of Medicine) Melanoma is the deadliest form of skin cancer and notorious for its resistance to conventional chemotherapy. Approximately 25 percent of melanoma is driven by oncogenic mutations in the NRAS gene, making it a very attractive therapeutic target. However, despite decades of research, no effective therapies targeting NRAS have been forthcoming.

Decreased 5-hydroxymethylcytosine immunoreactivity in primary Merkel cell carcinomas is a strong predictor for disease-specific death. This article is protected by copyright. All rights reserved. PMID: 30703276 [PubMed – as supplied by publisher]



Please signin to view all article content and metadata.


Leave a Comment